Advances in cystic fibrosis-related diabetes: Current status and future directions
Diabetes & Metabolic Syndrome: Clinical Research & Reviews · 2023
DOI: 10.1016/j.dsx.2023.102899 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 2023. Verfasst von F Lurquin und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Nutrition, Cliniques Universitaires Saint-Luc, Institut de Recherche Expérimentale et Clinique, UCLouvain, Brussels, …. Hauptthemen laut MEDLINE: Glucose Intolerance, Cystic Fibrosis, Diabetes Mellitus. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Cliniques universitaires Saint-Luc.
Themen: Diabetes mellitus
Abstract (Originalsprache)
AIMS: The aim of this review is to give an update of the recent advances in the pathophysiology, prognosis, diagnosis and treatments of cystic fibrosis-related diabetes (CFRD). METHODS: The literature survey focuses on original and review articles dealing with CFRD between 2006 and 2023, and in particular with: pathophysiology, risk and predictive factors, screening, chronic complications of CFRD, management and the effects of CFTR channel modulator therapies on glucose homeostasis, using PubMed®. RESULTS: The rising prevalence of CFRD is due to prolonged life survival among patients with cystic fibrosis (CF). Advances in the understanding of the pathophysiology highlight the singularity of CFRD. Adherence to diagnostic guidelines remains challenging. Besides the classical OGTT, alternative diagnostic tests are being considered: HbA1c measurement, continuous glucose monitoring (CGM), intermediate measurements of alternative glucose tolerance stages through OGTT and homeostatic model assessment (HOMA). Early treatment of (pre)diabetes in CF patients is mandatory. The advent of CFTR channel modulator therapies have created a paradigm shift in the management of CF: they seem to improve glucose homeostasis, but the mechanism remains unclear. CONCLUSION: CFRD management is an ongoing concern. Optimal care has reduced the negative impact of CFRD on lung function, nutrition, and survival. Increasing prevalence of CFRD and prolonged lifespan lead to more microvascular complications. New screening tools (Hba1c, CGM, HOMA) show potential for better classification of patients. The effect of CFTR modulators on glucose metabolism warrants further research.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology and Nutrition, Cliniques Universitaires Saint-Luc, Institut de Recherche Expérimentale et Clinique, UCLouvain, Brussels, Belgium. Electronic address: fabian.lurquin@saintluc.uclouvain.be.
- Department of Endocrinology and Nutrition, Cliniques Universitaires Saint-Luc, Institut de Recherche Expérimentale et Clinique, UCLouvain, Brussels, Belgium.
Förderung
- Cliniques universitaires Saint-Luc
Zitieren
APA
Lurquin, F., Buysschaert, M., & Preumont, V. (2023). Advances in cystic fibrosis-related diabetes: Current status and future directions. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. https://doi.org/10.1016/j.dsx.2023.102899
Vancouver
Lurquin F, Buysschaert M, Preumont V. Advances in cystic fibrosis-related diabetes: Current status and future directions. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2023. doi:10.1016/j.dsx.2023.102899
BibTeX
@article{Lurquin2023,
author = {Lurquin, F and Buysschaert, M and Preumont, V},
title = {Advances in cystic fibrosis-related diabetes: Current status and future directions},
journal = {Diabetes & Metabolic Syndrome: Clinical Research & Reviews},
year = {2023},
doi = {10.1016/j.dsx.2023.102899}
}
EUVIMED